Noam Krantz is Vice President of Venture Investments for Johnson and Johnson Development Corporation (JJDC), where he is responsible for initiating and managing equity investments to drive business innovation and deliver new and sustainable business for the Medical Device sector. 

Noam has completed over $70 billion in high value growth-oriented transactions, in fields ranging from medical devices and pharmaceuticals to semiconductors and software.  In his most recent role as VP, Business Development, he added many platforms and technologies to Ethicon’s portfolio, including those in digital surgery (3Di, Auris investment), GERD (Torax), Interventional Oncology (NeuWave, Auris collaboration), Wound Closure (barbed sutures) and Energy (Megadyne).

​

Noam’s career spans almost 20 years of mergers & acquisitions, business development and management in the healthcare field. He began in Bear Stearns & Co.’s New York investment banking division in 2001, where he worked on advising healthcare and technology companies on M&A and corporate finance transactions. In 2004, he joined Inamed Corporation, as a Senior Manager of Strategy and Corporate Development, and then moved to Mentor Corporation, where he was Vice President of the company’s Corporate Development group, running the Company’s investor relations effort.

​

Noam has a BS in Biological Sciences from University of California Santa Barbara and an MBA from Columbia Business School.